SCHEMBL5540149

SCHEMBL5540149

COc1cccc(O[CH]c2ccccc2)c1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 5/20 0.57
TUBB4A P04350 5/20 0.53
TUBB P07437 5/20 0.53
TUBA3C P0DPH7 5/20 0.53
TUBA1B P68363 5/20 0.53
TUBA4A P68366 5/20 0.53
TUBB4B P68371 5/20 0.53
TUBB3 Q13509 5/20 0.53
TUBB2A Q13885 5/20 0.53
TUBB8 Q3ZCM7 5/20 0.53
TUBA3E Q6PEY2 5/20 0.53
TUBA1A Q71U36 5/20 0.53
TUBA1C Q9BQE3 5/20 0.53
TUBB6 Q9BUF5 5/20 0.53
TUBB2B Q9BVA1 5/20 0.53
TUBB1 Q9H4B7 5/20 0.53
TRPA1 O75762 1/20 0.46
TNFRSF1A P19438 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5534728 0.89 NFE2L2 (0.56) NFE2L2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL5547846 0.84 CA1 (0.56) NFE2L2TUBB4ATUBBTUBA3CTUBA1B
Benzaldehyde SCHEMBL27773248 0.79 NFE2L2 (0.59) NFE2L2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL25434306 0.77 CA1 (0.61) NFE2L2CA12CA1CA2CA4
SCHEMBL151213 0.77 CA1 (0.61) NFE2L2CA12CA1CA2CA4
SCHEMBL27753904 0.77 CA1 (0.61) NFE2L2CA12CA1CA2CA4
SCHEMBL7056824 0.76 SMN1; SMN2 (0.47) NFE2L2TUBB4ATUBBTUBA3CTUBA1B
Ammonia Solution, Strong SCHEMBL4268652 0.75 SMN1; SMN2 (0.58) NFE2L2CA12CA1CA2CA4
Hydrochloric Acid SCHEMBL31658961 0.75 SMN1; SMN2 (0.58) NFE2L2CA12CA1CA2CA4
Bromide SCHEMBL28158222 0.75 SMN1; SMN2 (0.58) NFE2L2CA12CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NFE2L2 846/4885TUBB4A 917/4885TUBB 446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.